New drug combo HRS8807 and SHR6390 targets tough breast cancer

NCT ID NCT04993430

Ongoing Disease control Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called HRS8807, alone or with another drug SHR6390, in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to find safe doses and check for side effects. Participants have already tried hormone therapy and up to two chemotherapy treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS8807 (a drug) and SHR6390 (a drug)
What this could lead to: If it works, this could point toward a new treatment option for people with ER-positive, HER2-negative advanced breast cancer.
What could go wrong: This is a very early Phase 1 trial with only 46 people, so it is mainly checking safety and dosing. It may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER-POSITIVE HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ER-POSITIVE HER2-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.